Key Points
- Arnold Baskies, a director of Anixa Biosciences, bought 10,000 shares on Jan. 28 at an average price of $3.04, increasing his stake to 135,000 shares (an 8% rise); the purchase was disclosed in an SEC filing.
- ANIX is trading around $3.10 with a market cap of about $103.5M, reported -$0.09 EPS last quarter (analysts expect -$0.41 for the year), and carries an average analyst rating of Hold with a $9 consensus price target.
- Anixa is a clinical‑stage immuno‑oncology and infectious disease company advancing cell‑based immunotherapies, a VLP COVID‑19 vaccine, and the ADAPT high‑throughput proteomics diagnostic platform.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Arnold Baskies bought 10,000 shares of the company's stock in a transaction that occurred on Wednesday, January 28th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director owned 135,000 shares of the company's stock, valued at $410,400. The trade was a 8.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Anixa Biosciences Trading Up 2.3%
ANIX opened at $3.10 on Friday. Anixa Biosciences Inc has a 12-month low of $2.33 and a 12-month high of $5.46. The firm has a 50 day moving average of $3.67 and a two-hundred day moving average of $3.59. The firm has a market capitalization of $103.48 million, a PE ratio of -8.86 and a beta of 0.49.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its quarterly earnings data on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). As a group, analysts predict that Anixa Biosciences Inc will post -0.41 EPS for the current fiscal year.
Hedge Funds Weigh In On Anixa Biosciences
Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its position in shares of Anixa Biosciences by 1.7% in the third quarter. Bank of America Corp DE now owns 213,955 shares of the company's stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. GSA Capital Partners LLP grew its stake in Anixa Biosciences by 4.9% in the 3rd quarter. GSA Capital Partners LLP now owns 81,897 shares of the company's stock valued at $270,000 after acquiring an additional 3,790 shares during the period. Prosperity Wealth Management Inc. increased its holdings in Anixa Biosciences by 14.5% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company's stock worth $138,000 after acquiring an additional 5,300 shares in the last quarter. Westside Investment Management Inc. raised its position in Anixa Biosciences by 25.7% during the fourth quarter. Westside Investment Management Inc. now owns 44,000 shares of the company's stock worth $137,000 after acquiring an additional 9,000 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company's stock valued at $35,000 after purchasing an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on ANIX shares. D. Boral Capital reissued a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Friday, December 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Anixa Biosciences in a report on Monday, December 29th. Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, January 17th. Finally, Zacks Research lowered shares of Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 18th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $9.00.
Check Out Our Latest Stock Analysis on Anixa Biosciences
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
